期刊文献+

西地那非治疗新生儿持续肺动脉高压疗效观察 被引量:8

Observation of Sildenafil for Treating Persistent Pulmonary Hypertension
下载PDF
导出
摘要 目的 探讨西地那非治疗新生儿持续性肺动脉高压(PPHN)的疗效。方法 选取2012年1月至2013年4月我院新生儿科收治的PPHN患者32例,根据有无使用西地那非分成2组(治疗组15例,对照组17例),对照组采用常规治疗,治疗组在常规治疗的基础上加用西地那非治疗,西地那非管喂给药,0.5-1mg/(kg·次),6-8h1次,每次用药前后30min监测血压。观察两组患者的治疗前及治疗3d后动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)和动脉血氧饱和度(Sa02)的变化,肺动脉平均压(PAMP)及总有效率。结果 治疗后3d,治疗组肺动脉平均压(PAMP)、PaCO2显著低于对照组,差异有统计学意义(P〈0.01),SaO2、PaO2显著高于对照组,差异有统计学意义(P〈0.01)。总有效率治疗组(80.0%)显著高于对照组,差异有统计学意义(44.4%)。结论 口服西地那非治疗PPHN可有效降低肺动脉压力,提高血氧饱和度,具有良好的治疗效果。 Objective To investigate the clinical efects of Sildenafil for treating persistent pulmonary ypertension. Meth-ods Selected 32 patients diagnosed with PPHN in our department between January 2012 and April 2013,then,According to whether using sildenafil divided them into two groups( the sildenafil group were 15 cases,control group were 17 cases). the control group given general treatment,the sildenafil group were treated with sildenafil on the basis of general treatment,the use of sildenafil dose was 0. 5-1. 0 mg/kg,drop into the inside of the feed tube. Before using sildenafil and afer three days,observed the change of arterial blood PaCO 2﹑PaO 2﹑SaO 2 and PAMP. we also calculate the total effective. Results After three days,the arterial blood PaO 2﹑SaO 2 of the sildenafil group were significantly increased,the arterial blood PaCO 2﹑PAMP were decreased significantly compared with the control group(P 〈0. 05). The total effective of the sildenafil group was higher than the control group(P 〈0. 05 ) . Conclusion Sildenafil for treating PPHN can effectively reduce the pulmonary artery pressure,improve blood oxygen saturation,has a good therapeutic effect.
作者 郭琳
出处 《四川医学》 CAS 2014年第9期1195-1197,共3页 Sichuan Medical Journal
关键词 西地那非 持续性肺动脉高压 新生儿 sildenafil persistent pulmonary ypertension newborn
  • 相关文献

参考文献10

二级参考文献31

  • 1Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol,2004,43( 12 Suppl S) :68S-72S.
  • 2Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med,2004,351 (14) :1425-1436.
  • 3Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitricoxide, and iloprost in primary pulmonary hypertension. Chest, 2004,125 ( 2 ) : 580 -586.
  • 4Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension:acute and midterm effects. Eur Heart J,2004,25 ( 5 ) : 431-436.
  • 5Michelakis ED, Tymchak W, Noga M, et al, Long-term treatment with oral silednafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation, 2003,108 ( 17 ) : 2066-2069.
  • 6Meng L K,Liu C G.Gene therapies for pulmonary hypertension-from experimental trials to bedside aspects[J].Eur J Cardio-Thorac,2010,37(2):407-419.
  • 7Rabinovitch M.Pulmonary hypertension:updating a mysterious disease[J].Cardiovas Res,1997,34(2):268-272.
  • 8Rabinovitch M,Haworth S G,Castaneda A R,et al.Lung biopsy in congenital heart disease:a morphometric approach to pulmonary vascular disease[J].Circulation,1978,58(6):1107-1122.
  • 9Rabinovitch M.Molecular pathogenesis of pulmonary arterial hypertension[J].J Clin Invest,2008,118(7):2372-2379.
  • 10Garcia R,Diebold S.Simple,rapid,and effective method of producing aortocaval shunts in the rat[J].Cardiovas Res,1990,24(5):430-432.

共引文献62

同被引文献50

引证文献8

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部